Nabsys raises $21m equity funding led by Hitachi High-Technologies

– USA, RI –  Nabsys, the pioneer in high-definition genome mapping, today announced that it has closed on a $21 million equity round led by Hitachi High-Technologies Corporation.

“This investment round will help Nabsys fulfill its mission to make the analysis of large- and intermediate-scale genomic variation as routine, accurate, and cost-effective as the analysis of single-nucleotide variation,” said Barrett Bready, M.D., Founder and CEO at Nabsys.

Nabsys will use the funding to finalize product development and support the global commercial launch of their HD-Mapping™ whole-genome electronic mapping platform.

HD-Mapping has applications in a wide variety of key research applications, including de novo assembly, structural variant analysis, metagenome characterization, and strain identification, as well as in next-generation cytogenetics. Nabsys electronic mapping enables routine, scalable analysis of genomic structural variation.

Mr. Tsuyoshi Ogino, General Manager, Innovation Division at Hitachi High-Technologies said, “There is a strong need for accurate, robust, and scalable genomic structural analysis for cytogenetic, cancer, and infectious disease research. Hitachi High-Technologies determined that the Nabsys HD-Mapping approach effectively supports this need. The company is also a strong fit with our strategy for continued advanced R&D with strategic investments in life sciences.”

About Hitachi High-Technologies Corporation

Hitachi High-Technologies Corporation, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, including Analytical & Medical Solutions (manufacture and sales of clinical analyzers, biotechnology products, and analytical instruments), Nano-Technology Solutions (manufacture and sales of semiconductor manufacturing equipment and analysis equipment), and Industrial Solutions (providing high value-added solutions in fields of social & industrial infrastructures and mobility, etc.). The company’s consolidated revenues for FY 2018 were approx. JPY 731.1 billion [USD 6.6 billion].

For more information, visit

About Nabsys

Nabsys is the leader in high-definition electronic genome mapping. Nabsys uses proprietary electronic nanochannel detectors to analyze long DNA molecules at high velocity. Nabsys HD-Mapping™ whole-genome maps with the sub-diffraction-limit resolution, provide compelling advantages for the analysis of genomic structural variation, genome assembly, and high-specificity strain identification.

For more information, visit

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Related Posts

Comments are closed.